Global Montelukast Drug Market Size By Type (Tablet, Chewable tablet), By Application (Hospital, Drug store), By Region, And Segment Forecasts, 2023 to 2032

The Global Montelukast Drug Market was valued at USD 6.3 billion in 2023 and is projected to reach USD 10.4 billion by 2031, expanding at a CAGR of 6.7% during the forecast period from 2023 to 2031. The market growth is primarily driven by the increasing prevalence of asthma and allergic rhinitis, growing awareness about respiratory disorders, and the rising adoption of generic drugs across emerging economies. Montelukast, a leukotriene receptor antagonist (LTRA), is widely prescribed for chronic asthma, exercise-induced bronchoconstriction, and seasonal allergies, offering a cost-effective alternative to corticosteroids and antihistamines.

Drivers:

1. Rising Incidence of Respiratory Disorders:

A growing global burden of respiratory illnesses such as asthma, allergic rhinitis, and bronchospasm is fueling demand for Montelukast. Urbanization, pollution, and climate change contribute to this trend.

2. Growth in Generic Drug Manufacturing:

As patents for branded drugs expire, the entry of generic Montelukast products by pharmaceutical companies is making treatments more accessible and affordable, particularly in price-sensitive markets.

3. Increased Healthcare Access in Emerging Markets:

Improved healthcare infrastructure and insurance coverage are enabling more individuals in developing countries to receive treatment for chronic respiratory conditions.

Restraints:

1. Side Effects and Product Recalls:

Montelukast has been associated with neuropsychiatric side effects in some patients, including mood swings and suicidal thoughts, which can limit its prescription and market uptake.

2. Regulatory Scrutiny and Label Warnings:

Tighter regulations and black-box warnings issued by authorities such as the FDA have prompted healthcare professionals to exercise caution, slightly tempering demand growth.

Opportunity:

1. Expansion into Pediatric and Geriatric Segments:

Montelukast is gaining traction in pediatric and elderly populations due to its once-daily oral dosage form and tolerability. Continued clinical research and approvals for broader age groups represent untapped growth potential.

2. Rising Demand for Combination Therapies:

Innovations combining Montelukast with antihistamines or corticosteroids are gaining momentum, particularly for treating complex allergic conditions, opening new market avenues.

Market by System Type Insights:

By formulation, oral tablets dominated the market in 2023 due to their convenience and widespread availability. The chewable tablets segment is expected to witness the highest growth rate, especially among pediatric populations. Rapid-dissolving tablets and granules are also emerging as popular dosage forms, offering alternatives for patients with swallowing difficulties.

Market by End-use Insights:

The retail pharmacies segment held the largest market share in 2023, benefiting from the wide distribution of over-the-counter (OTC) Montelukast in some regions. Hospital pharmacies are also significant, especially in chronic and acute respiratory treatment programs. Online pharmacies are expected to see accelerated growth due to the global trend of e-pharmacy adoption and convenience in drug delivery.

Market by Regional Insights:

North America accounted for the largest share of the global Montelukast drug market in 2023, driven by high awareness levels, regulatory approvals, and robust healthcare infrastructure. Asia-Pacific is expected to grow at the fastest CAGR during the forecast period, fueled by increasing asthma incidence, generic drug production, and favorable government initiatives in India and China. Europe remains a strong market, supported by universal healthcare systems and high generic drug penetration.

Competitive Scenario:

Key players in the Global Montelukast Drug Market include Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Aurobindo Pharma, Cipla Inc., Sun Pharmaceutical Industries Ltd., Glenmark Pharmaceuticals, Dr. Reddy’s Laboratories, Torrent Pharmaceuticals, and Sandoz (a Novartis division). Companies are focusing on expanding their generic drug portfolios, entering strategic partnerships, and securing regulatory approvals to gain a competitive edge.

Scope of Work – Global Montelukast Drug Market

Key Market Developments:

2023: Merck announced clinical data for extended-release Montelukast formulations targeting improved nighttime symptom control.

2024: Cipla launched pediatric Montelukast chewables in key Asian markets, focusing on affordability and palatability.

2025: Glenmark partnered with a US-based biotech firm to co-develop Montelukast-antihistamine combination therapies.

FAQs:

1. What is the current market size of the Global Montelukast Drug Market?

The market was valued at USD 6.3 billion in 2023.

2. What is the major growth driver of the Global Montelukast Drug Market?

The rising prevalence of asthma and allergic rhinitis globally is a primary growth driver.

3. Which is the largest region during the forecast period in the Global Montelukast Drug Market?

North America holds the largest market share, with Asia-Pacific expected to grow the fastest.

4. Which segment accounted for the largest market share in the Global Montelukast Drug Market?

The oral tablets segment accounted for the largest share by formulation, and retail pharmacies by end-use.

5. Who are the key market players in the Global Montelukast Drug Market?

Key players include Merck, Teva, Cipla, Aurobindo Pharma, Glenmark, and Dr. Reddy’s Laboratories.